61478-27-1

Basic information

• Product Name: 1-Pyrrolidinecarboxylic acid, 4-[[(4-methylphenyl)sulfonyl]oxy]-2-[[[(4-methylphenyl)sulfonyl]oxy]methyl] -, 1,1-dimethylethyl ester, (2S,4R)-
• Synonyms: N-(t-Butoxycarbonyl)-trans-4-hydroxy-L-prolinol di-p-toluenesulfonate;(2S,4R)-N-tert.-butoxycarbonyl-4-tosyloxy-2-tosyloxymethylpyrrolidine;N-(tert-Butoxycarbonyl)-4-hydroxy-L-prolinol Di-p-toluenesulfonate;(2S,4R)-tert-butyl 4-(tosyloxy)-2-(tosyloxymethyl)pyrrolidine-1-carboxylate;(2S,4R)-N-tert-butoxycarbonyl-4-tosyloxy-2-tosyloxymethylpyrrolidine;(2R,4S)-N-(tert-Butoxycarbonyl)-4-tosyloxy-2-tosyloxymethylpyrrolidine
• CAS NO: 61478-27-1
• Molecular Formula: C24H31NO8S2
• Molecular Weight: 525.644
• Mol File: 61478-27-1.mol

Chemical Properties

• Boiling Point: 654.4±50.0 °C(Predicted)
• Density: 1.35±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 1-Pyrrolidinecarboxylic acid, 4-[[(4-methylphenyl)sulfonyl]oxy]-2-[[[(4-methylphenyl)sulfonyl]oxy]methyl] -, 1,1-dimethylethyl ester, (2S,4R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Pyrrolidinecarboxylic acid, 4-[[(4-methylphenyl)sulfonyl]oxy]-2-[[[(4-methylphenyl)sulfonyl]oxy]methyl] -, 1,1-dimethylethyl ester, (2S,4R)-(61478-27-1)
• EPA Substance Registry System: 1-Pyrrolidinecarboxylic acid, 4-[[(4-methylphenyl)sulfonyl]oxy]-2-[[[(4-methylphenyl)sulfonyl]oxy]methyl] -, 1,1-dimethylethyl ester, (2S,4R)-(61478-27-1)

Safety Data

• Hazardous Substances Data: 61478-27-1(Hazardous Substances Data)

Usage

Molecular structure

The compound has a pyrrolidinecarboxylic acid core, connected to a 4-methylphenylsulfonyl group and a 1,1-dimethylethyl ester.

Stereochemistry

The compound's stereochemistry is specified as (2S,4R), indicating the spatial arrangement of its atoms.

Potential applications

The compound may have applications in the pharmaceutical or chemical industries due to its complex structure and suggested potential biological activity.

Further research

Additional research and testing are required to fully understand the properties and potential uses of this chemical.

Upstream product

• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 13726-69-7 (2S,4R)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid 
• 61478-25-9 (2S,4R)-4-hydroxypyrrolidine-2-carboxylic acid ethyl ester 
• 51-35-4 4R-4-hydroxyproline 
• 37813-30-2 (2S,4R)-4-hydroxyproline-1,2-dicarboxylic acid 1-tert-butyl 2-ethyl ester 
• 33996-30-4 trans-4-hydroxy-L-proline ethyl ester hydrochloride 
• 1070-19-5 N-(tert-butyloxycarbonyl) azide 
• 61478-26-0 tert-butyl (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine-1-carboxylate 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 84127-05-9 (2S,4S)-4-[Bis-(4-methoxy-phenyl)-phosphanyl]-2-{[bis-(4-methoxy-phenyl)-phosphanyl]-methyl}-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 119751-59-6 (2S,4S)-N-tert.-butoxycarbonyl-4-bis(3-methoxyphenyl)phosphino-2-bis(3-methoxyphenyl)phosphinomethylpyrrolidine 
• 119751-58-5 (2S,4S)-N-tert.-butoxycarbonyl-4-bis(2-methoxyphenyl)phosphino-2-bis(2-methoxyphenyl)phosphinomethylpyrrolidine 
• 244768-98-7 2-tert-butoxycarbonyl-5-methyl-2,5-diazabicyclo[2.2.1]heptane 
• 1217827-86-5 2-benzyl-2,5-diazabicyclo[2.2.1]heptane dihydrochloride 
• 1024010-91-0 ethyl 4-((1R,4R)-5-benzyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)benzoate 
• 1024010-93-2 ethyl 4-((1R,4R)-2,5-diazabicyclo[2.2.1]heptan-2-yl)benzoate formate 
• 1024010-94-3 ethyl 4-((1R,4R)-5-m-tolyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)benzoate 
• 1024008-03-4 N-hydroxy-4-((1R,4R)-5-m-tolyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)benzamide 
• 134003-83-1 tert-butyl (1R,4R)-5-benzyl-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate 
• 125653-57-8 (2S,4R)-N-tert.-butoxycarbonyl-2-bis(4-dimethylaminophenyl)phosphinomethyl-4-tosyloxypyrrolidine 
• 125653-56-7 (2S,4R)-N-tert.-butoxycarbonyl-2-diphenylphosphinomethyl-4-tosyloxypyrrolidine 
• 125653-50-1 (2S,4S)-N-tert.-butoxycarbonyl-4-bis(3,5-dimethyl-4-methoxyphenyl)phosphino-2-diphenylphosphinomethylpyrrolidine 
• 5260-20-8 (1S,4S)-2,5-Diazabicyclo<2.2.1>heptane dihydrochloride 

Relevant articles and documents

Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase

This disclosure relates to compounds for the inhibition of histone deacetylase and treatment of a cognitive disorder or deficit. More particularly, the disclosure provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.

HDAC INHIBITORS AND USES THEREOF

Inhibitors of histone deacetylase, including compounds having a diazabicyclo[2.2.1]heptan-2-yl moiety are described together with methods for treating various disorders with such compounds.

SUBSTITUTED DIAZABICYCLOHEPTANES AND THEIR USE AS PROTEIN KINASE INHIBITORS

The present invention relates to therapeutic diazobicyclo pyridines and their use in the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis or osteoarthritis, organ transplant, acute transplant or heterograft and homograft rejection, ischemic and reperfusion injury, transplantation tolerance induction, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, lupus, graft vs. host diseases, T -cell mediated hypersensitivity diseases, contact hypersensitivity, delayed-type hypersensitivity, gluten-sensitive enteropathy, Type 1 diabetes, psoriasis, contact dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism,Graves' Disease, Addison's disease, autoimmune polyglandular disease, autoimmune alopecia, pernicious anemia, vitiligo, autoimmune hypopituatarism, Guillain-Barre syndrome, autoimmune diseases, glomerulonephritis, serum sickness, uticaria, respiratory allergies, asthma, hayfever, allergic rhinitis, skin allergies, scleracielma, mycosis fungoides, acute inflammatory responses, acute respiratory distress syndrome, dermatomyositis, alopecia areata, chronic actinic dermatitis, eczema, Behcet's disease, Pustulosis palmoplanteris, Pyoderma gangrenum, Sezary's syndrome, atopic dermatitis, systemic schlerosis, morphea, Type II diabetes and cancers where PKC theta or other PKC-family kinases are activated, overexpressed or facilitate tumor growth or survival of tumor cells, T cell leukemia, thymoma, T and B cell lymphoma, colon carcinoma, breast carcinoma and lung carcinoma or provides resistance to chemotherapeutic drugs.

Transition-Metal-Catalyzed Asymmetric Organic Synthesis via Polymer-Attached Optically Active Phosphine Ligands. 5. Preparation of Amino Acids in High Optical Yield via Catalytic Hydrogenation

Two new optically active phosphinopyrrolidine monomers were prepared by the reaction of (2S,4S)-4-(diphenylphosphino)-2-pyrrolidine and (2R,4R)-4-(diphenylphosphino)-2-pyrrolidine with acryloyl chloride to give N-acryloyl-(2S,4S)-4-(diphenylphosphino)-2-pyrrolidine (1) and N-acryloyl-(2R,4R)-4-(diphenylphosphino)-2-pyrrolidine (2).Copolymerization of 1 and 2 with hydrophilic comonomers and a divinyl monomer provided cross-linked insoluble polymers containing 3-5percentof 1 or 2 that would swell in polar solvents.Exchange of rhodium (I) onto the polymer gave catalysts which were active for the asymmetric hydrogenation of N-acyl α-amino acids in high optical yields, the phosphine derived from the enantiomer of the naturally occurring 4-hydroxyproline giving (S)-amino acids.The catalysts could be reused with no loss in selectivity by simple filtration.

Asymmetric Hydrogenation of Prochiral Olefins Catalyzed by Rhodium Complexes with Chiral Pyrrolidinodiphosphines. Crucial Factors for the Effective Asymmetric Induction

Remarkable effects of hydrogen pressure on the stereoselectivity were observed in the asymmetric hydrogenations of itaconic acid, α-(acylamino)acrylic acid, and their derivatives catalyzed by rhodium complexes of chiral pyrrolidinodiphosphines.Effects of added triethylamine on the pressure dependency of stereoselectivity were also studied.Marked differences in the direction of asymmetric induction were found in the asymmetric hydrogenations of the methylsuccinic acid precursors itaconic acid, citraconic acid, and mesaconic acid.This result clearly indicates that the chiral recognition by the rhodium catalyst is extremely sensitive to the stereochemistry of the prochiral olefins.Possible mechanisms are discussed on the basis of these results. 31PNMR studies on the key intermediates in asymmetric hydrogenations have revealed that the mode of the bidentate complexation of the prochiral substrates is extremely regioselective.The "induced-fit" phenomena of the chiral rhodium complex were observed.A possible mechanism for the chiral recognition of enantiofaces in the chiral coordination sphere is proposed.